Ascl1 phospho-status regulates neuronal differentiation in a Xenopus developmental model of neuroblastoma by Wylie, Luke A et al.
RESEARCH ARTICLE
Ascl1 phospho-status regulates neuronal differentiation in a
Xenopus developmental model of neuroblastoma
Luke A. Wylie1,2, Laura J. A. Hardwick1, Tatiana D. Papkovskaia1, Carol J. Thiele2 and Anna Philpott1,*
ABSTRACT
Neuroblastoma (NB), although rare, accounts for 15% of all paediatric
cancer mortality. Unusual among cancers, NBs lack a consistent
set of gene mutations and, excluding large-scale chromosomal
rearrangements, the genome seems to be largely intact. Indeed,
many interesting features of NB suggest that it has little in commonwith
adult solid tumours but instead has characteristics of a developmental
disorder. NB arises overwhelmingly in infants under 2 years of age
during a specific window of development and, histologically, NB bears
striking similarity to undifferentiated neuroblasts of the sympathetic
nervous system, its likely cells of origin. Hence,NBcould beconsidered
a disease of development arising when neuroblasts of the sympathetic
nervous system fail to undergo proper differentiation, but instead are
maintained precociously as progenitors with the potential for acquiring
further mutations eventually resulting in tumour formation. To explore
this possibility, we require a robust and flexible developmental model to
investigate the differentiation of NB’s presumptive cell of origin. Here,
we use Xenopus frog embryos to characterise the differentiation of
anteroventral noradrenergic (AVNA) cells, cells derived from the neural
crest. We find that these cells share many characteristics with their
mammalian developmental counterparts, and also with NB cells. We
find that the transcriptional regulator Ascl1 is expressed transiently in
normal AVNA cell differentiation but its expression is aberrantly
maintained in NB cells, where it is largely phosphorylated on multiple
sites. We show that Ascl1’s ability to induce differentiation of AVNA
cells is inhibited by its multi-site phosphorylation at serine-proline
motifs, whereas overexpression of cyclin-dependent kinases (CDKs)
and MYCN inhibit wild-type Ascl1-driven AVNA differentiation, but not
differentiation driven bya phospho-mutant formof Ascl1. This suggests
that the maintenance of ASCL1 in its multiply phosphorylated state
might prevent terminal differentiation in NB, which could offer new
approaches for differentiation therapy in NB.
KEY WORDS: Ascl1, Xenopus, Cell cycle, Development,
Differentiation, Neuroblastoma
INTRODUCTION
Neuroblastoma (NB) is a tumour of the autonomic nervous system
and is the most common cancer diagnosed in the first year of life.
Although the incidence of NB is considered to be relatively low,
with 10.2 cases per million children under the age of 15, it accounts
for 15% of all paediatric cancer mortality (Ries et al., 1999). A stark
dichotomy is seen among NB cases, with some forms undergoing
spontaneous regression and showing a strong response to treatment
whereas others progress to fatal metastasis and fail modern therapy
(Maris, 2010). Although substantial strides have been made in the
last 20 years, current treatment regimens are still inadequate or
unsuccessful for 40% of patients (Matthay et al., 1999). Early
genetic studies into NB revealed some large-scale chromosomal
rearrangements and amplifications in some tumours; most notably
MYCN amplification was found to be consistently associated with
poor prognosis in NB (Schwab et al., 1983). However, although
large-scale rearrangements and chromosomal losses are sometimes
observed, NB seems to lack a consistent set of mutations as seen in
many other cancers. Indeed, more recent large-scale sequencing
studies have revealed that NB tumours have an average of only
12 amino-acid-changing mutations per tumour, with the highest
recurring mutated gene, ALK, being mutated in only 6-10% of
tumours, suggesting that the genome of NB is largely intact
(Molenaar et al., 2012; Pugh et al., 2013).
If NB formation is not initiated by consistent genetic mutations,
then one possibility is that NB results from cells that are
developmentally arrested during noradrenergic (NA) neuron
differentiation, when the epigenetic landscape of precursor cells
promotes proliferation and inhibits terminal differentiation. Such a
scenario could explain why NB is seen largely only during
infancy, because the initial deviation from normal development
toward tumorigenesis can only occur during a specific time during
development. NB is thought to be derived from precursor cells of
the sympathetic nervous system (sympathetic progenitors) based
on the locations of primary tumours (Maris et al., 2007) and the
similar expression profile of NB to sympathetic progenitors (De
Preter et al., 2006). One might hypothesise that NA precursor cells
bypass their normal progression to terminal differentiation but
instead maintain their proliferative potential for an extended
period of time. As these cells continue to proliferate they might
acquire further epigenetic or genetic changes that result in cancer.
Supporting evidence for this view is the therapeutic use of retinoic
acid, a known inducer of neuronal differentiation in vivo, which
can result in neuronal differentiation and cell cycle arrest of NB
cells in vitro (Matsuo and Thiele, 1998; Thiele et al., 1985) and
improved survival in patients undergoing intensive chemotherapy
and radiation treatment (Matthay et al., 1999). In addition, recent
work has demonstrated that genes associated with differentiation
and inhibition of proliferation are epigenetically suppressed in NB
via PRC2, suggesting that there might be an epigenetic block
in these pathways rather than a genetic one (Wang et al., 2012).
However, existing therapies for NB are only partially effective
in aggressive disease and result in significant long-term
complications for NB patients, so more targeted therapies are
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If NB is a tumour partially derived from a failure to undergo the
appropriate developmental programme of differentiation, it becomes
imperative to understand what that developmental programme is, and
where it becomes arrested or disrupted in NB. The sympathetic
nervous system is derived from the neural crest (Howard, 2005;
Rohrer, 2011). These cells are difficult to characterise in mammals
because of their developmentally controlled migration and their
inaccessibility. To better understand the causes of NB and as a
platform to explore novel therapeutic approaches, research would
benefit greatly from a tractable experimental model to study normal
NA neuron differentiation and how it can be perturbed by
manipulations mimicking the situation in NB.
A number of developmental and embryonic stem (ES) cell model
systems are available to study normal development of the NA
nervous system, and these have been used to develop genetic models
of NB (Berry et al., 2012; Weiss et al., 1997; Zhu et al., 2012).
However, these models have not been widely used to understand
when and where during development NB cells arrest, and which
non-genetic intra- and extracellular changes in the developmental
environment might contribute to perturbation of the NA
differentiation programme. For such studies, one must combine
experimental embryology with the ability to perturb levels of cell
cycling and gene expression to investigate the effect on NA neuron
differentiation programmes. Therefore, a model system that is well-
characterised, allows for alteration in gene expression and protein
biochemistry, and permits analysis of large numbers of embryos at
multiple developmental stages is required. These requirements are
best represented by investigation of NA neuron development in
tadpoles of the frog Xenopus laevis.
Fortuitously, recent work has identified a set of NA precursor
cells in Xenopus embryos that express similar markers to the
developing mammalian sympathetic nervous system from which
NBs arise (Parlier et al., 2008). These cells express Ascl1, Phox2a,
Hand2 and tyrosine hydroxylase (TH), and are dependent on BMP
signalling, mirroring development of the sympathetic nervous
system in mammals (Howard, 2005; Rohrer, 2011). Here, we
demonstrate that this population of Xenopus NA cells is derived
from migrating neural crest, as is their mammalian counterpart. We
further explore the utility of this Xenopus system for characterising
normal NA development and differentiation of NA cells within the
signalling context of NB, by experimental manipulation of cyclin-
dependent kinase (CDK) and N-Myc levels on NA cell
differentiation, mimicking similar perturbations found in NB.
RESULTS
Migration of neural crest is required for expression of NA
markers in the anteroventral region
Parlier and colleagues identified a population of cells within the
anteroventral region of the Xenopus embryo that express a series of
markers [Ascl1 (Xash1), Phox2a, Hand2 and TH], suggesting that
they are an early component of the sympathetic nervous system, and
are hereby referred to as anteroventral noradrenergic (AVNA) cells
(Parlier et al., 2008). However, it was not clear whether these
cells arise de novo after induction by the underlying heart field or
whether they are, in fact, derived from migrating neural crest, as the
NB cells of origin are known to be (Howard, 2005; Rohrer, 2011;
Sarkar andHoward, 2006). To test this, we simultaneously injected a
dominant-negative form of Slug (dnSlug), which inhibits neural
crest migration (LaBonne and Bronner-Fraser, 2000), along with
β-galactosidase, serving as a tracer for injection, in one cell of the
two-cell-stage embryo, and then stained for the AVNA markers
Phox2a and Hand2 by in situ hybridisation. When comparing the
dnSlug-injected to the uninjected side of the embryo, neural crest
markers Slug, Snail and FoxD3 displayed more intense staining and
remained near the dorsal edge of the neural folds, demonstrating
inhibition of neural crest migration (Fig. 1A,B). In the presence of
dnSlug, we observed reduced expression of NAmarkers Phox2a and
Hand2, which are normally found in the ventral region (Fig. 1A,B).
Our data therefore indicate that the AVNA cells in Xenopus are
derived from neural crest and might represent a population of cells
analogous to the cells from which NB is thought to derive.
Ascl1 is expressed transiently during NA cell development in
the anteroventral region
If NB cells do represent a stalled stage of NA cell differentiation, it
is not clear at which developmental stage the cells are arrested.
To provide a framework to investigate this, we built on the initial
TRANSLATIONAL IMPACT
Clinical issue
Neuroblastoma (NB) is a paediatric cancer of infancy that occurs in
roughly 10.2 children per million. Although rare, NB still accounts
for 15% of all paediatric cancer mortality owing to its clinically
unfavourable outcome. Treatment for patients with poor prognosis, often
associated with MYCN (v-myc avian myelocytomatosis viral oncogene
neuroblastoma derived homolog) amplification, is inadequate in 40% of
cases. Therefore, new avenues for therapy should be explored. Whereas
most cancers arise froma rapid acquisition of genemutations, the genome
of NB is largely intact, suggesting a non-genetic cause for this disease.
Given that NB only arises during infancy and shows many histological
similaritieswith progenitor cells of the sympathetic nervous system, it could
represent a cancer driven by a failure in the normal developmental
programme. Understanding normal mechanisms that are involved in
sympathetic noradrenergic neuron development could give insight into NB
pathogenesis and might suggest new approaches to therapy.
Results
The authors describe a population of anteroventral noradrenergic
(AVNA) cells within Xenopus embryos that share common
characteristics with cells of the sympathetic nervous system of
mammals, the likely cell of origin for NB. They show that AVNA cells
derive from the neural crest and express a series of noradrenergic
genetic markers that are shared with NB cells. Interestingly, they show
that one of these genes, Ascl1 – achaete-scute complex-like 1, which
encodes a transcriptional driver of neurogenesis – is transiently
expressed during AVNA cell differentiation, but is aberrantly
maintained in NB. Building on previous studies characterising post-
translational regulation of Ascl1, the authors demonstrate that, although
Ascl1 is present in NB, it is phosphorylated on multiple serine-proline
sites and this inhibits its ability to drive AVNA cell differentiation.
In addition, the authors use the AVNA cell model system to test how
increased cyclin-dependent kinase (CDK; involved in cell cycle
regulation) and MYCN activity, found in NB, affects Ascl1’s ability to
induce differentiation. They find that ectopic AVNA cell differentiation
driven by Ascl1 is inhibited by increased CDK and MYCN activity, and
this inhibition depends on the phosphorylation of Ascl1.
Implications and future directions
This work has two important implications. First, it shows that the AVNA
model system offers a uniquely flexible system for analysing the initial
stages of sympathetic nervous system development, during which
NB is thought to arise. Secondly, it suggests that maintenance of
phosphorylation of ASCL1 on serine-proline sites in NB might
contribute to a failure of these cells to continue down their normal
developmental pathway and undergo terminal differentiation. Inhibition
of ASCL1 phosphorylation could therefore represent a new strategy to
enhance cell differentiation as a potential therapy in NB.
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analysis of Parlier and colleagues (2008) to further characterise the
developmental expression of the AVNA markers Phox2a, Hand2
and Ascl1 in Xenopus embryos by in situ hybridisation (Fig. 2).
Phox2b, although important during development of the sympathetic
nervous system in mammals (Pattyn et al., 1999; Unsicker et al.,
2005), was not expressed within the anteroventral region of Xenopus
embryos (Talikka et al., 2004). In addition, embryos were also
stained with Sox10, a marker of neural crest and early peripheral
nervous system development (Britsch et al., 2001; Southard-Smith
et al., 1998).
Firstly, Ascl1, Hand2, Phox2a and TH were all expressed within
the same anteroventral region of the embryo, consistent with the
identification of these cells as NA neurons. Furthermore, some
Sox10 expression was observed within the anteroventral region at
stage 14/15, which is consistent with its previously described role in
development of the peripheral nervous system and induction of
Ascl1 (Kim et al., 2003; Sonnenberg-Riethmacher et al., 2001),
although this expression was notably less pronounced than staining
in the central nervous system (supplementary material Fig. S1)
(Honoré et al., 2003). Phox2a and Hand2 were first expressed at
stage 12/13 and 16/17, respectively, and expression remained at
least until stage 23. Ascl1 was, however, expressed transiently, first
appearing at stage 14/15 and being downregulated by stage 16/17,
suggesting that its role during development is transient, much like its
mammalian counterpart (Guillemot et al., 1993). Thus, Ascl1 is
expressed at the onset of NA neuron differentiation but is rapidly
downregulated, and hence is well placed to play a role in the
progenitor maintenance versus differentiation decision specifically
at these early developmental stages.
p27Xic1 knockdown by morpholino injection inhibits
neurogenesis
Primary neurons are the first neurons to differentiate in the
developing Xenopus embryo and form in three stripes either side
of the mid-line within the dorsal neural plate (Vernon et al., 2003).
Expression of the CDK inhibitor (CDKI) p27Xic1 is absolutely
required for primary neuron differentiation, as assayed by staining
for neural-β-tubulin (Vernon et al., 2003). Conversely, when
p27Xic1 is overexpressed, extra primary neurons form at the
expense of maintenance of neural precursors (Vernon et al., 2003).
Fig. 1. Migration of neural crest is required for expression of noradrenergic markers in the anteroventral region. Xenopus embryos were injected in one
cell at the two-cell stage with β-galactosidase (light blue; A) as a tracer along with either GFP as a control, or mRNA encoding a dominant-negative form of
Slug (dnSlug) to inhibit neural crest migration; cells derived from the injected cell are shown in the side to the right in A. (A) Embryos were fixed at stage 17/18
and subject to in situ hybridisation for the neural crest markers Slug, Snail and FoxD3, and noradrenergic (NA) markers Phox2a and Hand2. (B) Embryos were
scored compared to the uninjected side based on inhibition of migration for neural crest markers and reduced expression of NA markers (see supplementary
material Fig. S3). For scoring data, n=28-45. Kruskal–Wallis non-parametric ANOVA was performed, comparing GFP control with dnSlug-injected embryos
(**P<0.0005 and ***P<0.000005).
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Similar to primary neurons, almost all mammalian neurons become
post-mitotic when they differentiate (Hardwick and Philpott, 2014).
However, sympathetic neurons are unique in that they retain their
ability to proliferate even after they express markers of mature
differentiation (Ernsberger et al., 1989). We investigated whether
the formation of AVNA cells has a lesser requirement for cell cycle
exit compared with primary neurons, and hence has this in common
with developing mammalian NA neurons. To test this, we inhibited
p27Xic1 translation using an antisense morpholino (MO), which
has been previously validated by western blotting and rescue
experiments in Xenopus embryos (Vernon et al., 2003), or we
increased the level of p27Xic1 by mRNA injection. We then
assayed for expression of neural-β-tubulin, a marker of primary
neuron differentiation, and also the later markers of NA
differentiation Hand2 and TH (Fig. 3). As we have previously
seen, p27Xic1-MO injection led to reduced expression of neural-β-
tubulin on the injected side, demonstrating a loss of primary neurons
compared with the contralateral uninjected side (Vernon et al.,
2003). This occurred in at least 25% of the injected embryos, with
an additional almost 30% of embryos showing an observable
decrease in neural-β-tubulin expression. The decrease in neural-β-
tubulin is consistent with a requirement for CDKIs in primary
neuron differentiation. However, a modest decrease in Hand2 and
TH induced by the p27Xic1 MO was detected in only 10-25% of
embryos. This indicates that primary neurons have a greater
requirement for CDKIs to support differentiation than do AVNA
cells.
We then investigated whether raising the level of p27Xic1 could
enhance AVNA cell specification and differentiation. High levels of
p27XicmRNA injected into one cell of two-cell embryos resulted in
Fig. 2. Ascl1 is expressed transiently during noradrenergic development in the anteroventral region. Xenopus embryos were fertilised and allowed to
develop to the developmental stage indicated before fixing and staining by in situ hybridisation for noradrenergic (NA) neuron markers Ascl1, Hand2, Phox2a and
TH, along with the neural crest marker Sox10. Embryos are all orientated with the ventral side imaged and head to the top. The anteroventral region where AVNA
cell markers are expressed is expanded in the lower panel.
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rapid cell cycle exit and cell death (Vernon et al., 2003). However,
lower levels of p27Xic1 slowed but did not arrest the cell cycle and
resulted in extra primary neurons differentiating within the neural
plate, particularly obvious at open neural plate stages (Vernon et al.,
2003) but also visible after neural tube closure in a minority of
embryos (Fig. 3). Injection of a low level of p27Xic1mRNA had no
effect on expression of Hand2, but there was a modest increase in
TH expression in p27Xic1-injected embryos in approximately 50%
of the embryos (Fig. 3). Taken together, these results indicate
that the differentiation of AVNA cells is less dependent on the
presence of CDKIs than is primary neurogenesis. This is consistent
with previous evidence showing that NA neurons can express
differentiation markers while still maintaining their ability to
proliferate (Ernsberger et al., 1989). Nevertheless, despite a
reduced requirement for cell cycle exit and CDK inhibition for
AVNA neurogenesis compared with primary neuron formation,
elevated levels of CDKIs can still modestly promote AVNA cell
differentiation. This led us to consider what influences the cell cycle
might have on differentiation of both sympathetic NA cells during
development and on NB cells under pathological conditions, as well
as potential mechanisms for such an influence.
NB expresses the proneural protein Ascl1 and NA markers
As described above, one possibility is that NB arises partially as a
consequence of arrested differentiation of sympathetic NA cells in
the developing peripheral nervous system. Determining when this
arrest occurs within the differentiation programme would prove
useful because it would help to identify potential pathways that
might be involved in the initial steps of NB tumorigenesis. Our data
indicate that Xenopus AVNA cells might represent an analogous
population to the sympathetic lineage from which NB arises that
would be more amenable to experimental manipulation than
mammalian NA precursors. We compared gene expression in NB
to ascertain whether this resembled an expression profile similar to a
particular stage of normal NA neuron development. We undertook
this by analysing the expression of NA markers that we
characterised in Xenopus AVNA development (Ascl1, Hand2,
Phox2a and TH; Fig. 2) in NB primary tumours, using publicly
available microarray data (Fig. 4). We found that NB primary
tumours have high expression of PHOX2A, HAND2 and TH.
Interestingly, although only transiently expressed in AVNA
development, NBs also have high levels of ASCL1 (Fig. 4A).
This suggests that NB is either stalled at a stage in development after
NA markers have been expressed, but prior to ASCL1
downregulation, or that ASCL1 is aberrantly actively maintained
at a high level.
We then investigated ASCL1 expression in a number of human
neural-derived tumours, again using publically available microarray
data (Fig. 4B). As well as a high level of expression in NBs, ASCL1
levels were also elevated in other neural-based tumours (glioma and
ependymoma), whereas other tumour types showed lower levels
(Fig. 4B) (Rheinbay et al., 2013). Although ASCL1 seemed to be
expressed across a number of NB primary tumours, we next verified
this in a panel of NB cell lines both at the mRNA and protein level.
All NB cells tested expressed variable levels of protein, with some
cell lines having substantially higher protein levels than others
(Fig. 4C). ASCL1 mRNA was also variably expressed in NB cell
lines (Fig. 4D), with the levels of mRNA correlating with the levels
of protein in the different NB cell lines. High levels of ASCL1 are
perhaps surprising because ASCL1 is most well-characterised for its
role in driving neuronal differentiation (Pang et al., 2011;
Vierbuchen et al., 2010), but NB cells continue to proliferate
despite having readily detectable levels of ASCL1. However,
ASCL1 has recently been shown to play a functional role in
Fig. 3. p27Xic knockdown by morpholino injection inhibits neurogenesis. Xenopus laevis embryos were injected in one cell at the two-cell stage with
β-galactosidase (light blue) as a tracer along with eitherXic1mRNA orXic1 antisensemorpholino (MO) as indicated; cells derived from the injected cell are shown
in the side to the right in A. (A) At stage 19/20, embryos were subject to in situ hybridisation to detect neural-β-tubulin, Hand2 and TH. Con MO, control MO.
(B) Embryos were scored for marker expression on the injected side relative to the uninjected side (see supplementary material Fig. S3 for scoring scheme).
For scoring data, n=12-34. Kruskal–Wallis non-parametric ANOVAwas performed on control MO compared to Xic1MO and uninjected compared to Xic1mRNA
(*P<0.05 and ***P<0.000005).
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maintaining ‘stemness’ in murine cortical neural stem cells (Castro
et al., 2011) and in human glioblastoma (Rheinbay et al., 2013),
indicating that ASCL1 expression does not always result in neuronal
differentiation. We have explored why NA neurons expressing high
levels of ASCL1 might nevertheless be inhibited from undergoing
neuronal differentiation, using NB cells and our Xenopus AVNA
system.
The ability of Ascl1 to drive neuronal differentiation in the central
nervous system is compromised by high levels of CDKs. We have
previously shown that Ascl1 is phosphorylated on multiple serine-
proline (SP) sites in Xenopus embryos and by CDKs in vitro
(Ali et al., 2014). Phosphorylation on these sites limits its ability
both to induce ectopic primary neurogenesis in Xenopus embryos
and to promote maturation of neurons generated from human
fibroblasts by a transcription-factor-mediated reprogramming
cocktail (Vierbuchen et al., 2010). To test whether phospho-
regulation of ASCL1 protein might be occurring in NB cells, we
investigated the phospho-status of ASCL1 in multiple NB cell lines.
ASCL1 is phosphorylated in NB lines
ASCL1mRNA and protein was detectable in all NB cell lines tested
but was found to be expressed at differing levels (Fig. 4C,D). To
investigate potential phosphorylation of ASCL1 in NB cells, we
used an assay to detect retarded migration on SDS polyacrylamide
gel electrophoresis (SDS PAGE), comparing results from before
and after phosphatase treatment, because retarded migration has
previously been shown to result from phosphorylation on SP sites
(Ali et al., 2011). To facilitate this analysis, protein samples from
Fig. 4C were loaded normalised to Ascl1 expression, allowing for
clear ASCL1 protein detection in all lines. Migration of ASCL1
on SDS PAGE was then compared with and without treatment
with the broad-spectrum lambda phosphatase to demonstrate
ASCL1 phosphorylation status (Fig. 5A). In all NB cell lines
tested, with the exception of SKNAS, ASCL1 migration was
enhanced by treatment with phosphatase. In several cell lines,
more than one retarded phospho-form was observed (e.g. NGP,
SKNDZ, SH-SYHY). In addition, it is noteworthy that different
cell lines showed a different pattern of migration of ASCL1
phospho-forms (e.g. compare NGP with SKNFI), indicating that
the pattern of post-translational modification of ASCL1 might
differ from cell line to cell line. We also observe that further post-
translational modification of ASCL1 occurs in some lines that is
not sensitive to phosphatase under the current conditions (e.g. in
NGP cells).
To determine whether the observed change in migration on SDS
PAGE was due to phosphorylation of serine-proline motifs in
Fig. 4. Neuroblastoma expresses the proneural protein ASCL1 and noradrenergic markers. Relative expression of ASCL1 and NA markers in
neuroblastoma (NB) primary tumours and normal tissue (A), and of ASCL1 across tumour types (B), were determined by analysing publicly available microarray
data (see Materials and Methods). The number of tumour samples used in the analysis are indicated next to the tumour type in B. ASCL1 expression in NB cell
lines and the Ewing sarcoma line TC-71, as a negative control, was determined by western blot (C) and qPCR (D).
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ASCL1, we created inducible SH-SY5Y cell lines that express
either human WT ASCL1 or a phospho-mutant form of ASCL1 in
which all five serine-proline motifs (see supplementary material
Fig. S2), potential targets of CDK-mediated phosphorylation (Ali
et al., 2014), are mutated to alanine-proline [serine to alanine (S-A)
ASCL1]. Expression of ASCL1 was then induced for 24 h and cell
extracts treated with and without phosphatase to observe any
potential change in ASCL1 SDS PAGE migration (Fig. 5B).
WT ASCL1 migrated more slowly than the phosphatase-treated
protein, whereas S-A ASCL1 migrated at the same level as the
de-phosphorylated WT ASCL1 protein and showed no detectable
sensitivity to phosphatase. This is consistent with phosphorylation
of ASCL1 on SP sites in NB cells. Phosphorylation on these sites
has previously been shown to be mediated by the CDK2 kinase
in vitro (Ali et al., 2014).
CDKactivity inhibits AVNA cell differentiation induced byWT
ASCL1 but not S-A ASCL1
Although AVNA cells seem to be less dependent on cell cycle exit
for differentiation compared to primary neurons, overexpression of
the CDKI p27Xic1 nevertheless promotes enhanced TH expression
(Fig. 3), indicating that CDK activity can influence AVNA cell
differentiation. This might be by CDK-dependent phosphorylation
and inactivation of ASCL1 (Ali et al., 2014). Elevated CDK levels
are known to inhibit neuronal differentiation in the CNS of Xenopus
and mammals (Lange et al., 2009; Richard-Parpaillon et al., 2004).
Our previous work demonstrated that high CDK activity inhibits
ASCL1’s ability to drive primary neurogenesis by phosphorylation
on SP sites ofWTASCL1, whereas S-AASCL1 can induce primary
neuron differentiation even when CDK kinase levels are raised (Ali
et al., 2014). We hypothesized that a similar mechanism might
regulate ASCL1’s ability to induce AVNA cell differentiation. We
first tested whether elevated CDK levels do indeed inhibit the
differentiation of AVNA cells in Xenopus.
To enhance CDK levels in Xenopus, we co-injected mRNA
encoding cyclin A2 and CDK2 into one cell of a two-cell embryo;
this has been previously shown to enhance kinase activity and cell
cycling (Ali et al., 2014; Richard-Parpaillon et al., 2004), and to
directly phosphorylate Ascl1 (Ali et al., 2014). Cyclin and CDK
overexpression delays but does not prevent primary neurogenesis
(Richard-Parpaillon et al., 2004), and led to a modest but clearly
observable decrease in endogenous Hand2 and Phox2a expression
in some embryos (Fig. 6). We also observed a more marked
reduction in TH expression, consistent with elevated CDK levels
suppressing particularly later stages of AVNA cell differentiation
(Fig. 6).
We then looked at the effect of elevated cyclin A2 and CDK2
levels on the differentiation of neurons generated by overexpression
of Ascl1, which results in ectopic generation of two distinct cell
populations. As previously reported, Ascl1 mRNA injection
resulted in increased expression of neural-β-tubulin dorsally in the
embryo, corresponding to generation of extra primary neurons (Ali
et al., 2014). Ectopic AVNA cells generated in the ventral region
by Ascl1 overexpression do not express neural-β-tubulin, but do
express Phox2a, Hand2 and TH, and so represent a population of
additional AVNA cells (Parlier et al., 2008). This demonstrates that
Ascl1 can drive differentiation of distinct populations of cells in
different regions of the Xenopus embryo.
Cyclin A and CDK2 efficiently suppressed the generation of
ectopic AVNA cells occurring after overexpression of WT Ascl1
(Fig. 6). However, S-A Ascl1 was largely insensitive to elevated
CDK levels, still generating extensive ectopic Hand2-, Phox2a- and
Fig. 5. ASCL1 is phosphorylated onmultiple sites in neuroblastoma cells. (A) Protein extracts from Fig. 4 were normalised based on ASCL1 expression and
treated with and without lambda phosphatase. Samples were then separated by SDS PAGE and subjected to western blotting for ASCL1 protein. (B) Human
ASCL1 or phospho-mutant S-A ASCL1 was overexpressed in SY5Y cells, and treated with and without lambda phosphatase. The slower migration observed on
SDS PAGE can be attributed to phosphorylation on SP sites.
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Fig. 6. CDK activity inhibits AVNA cell differentiation induced by WTASCL1 but not S-A ASCL1. Xenopus embryos were injected in one cell at the two-cell
stage with β-galactosidase (light blue; A) as a tracer along with mRNA encoding cyclin A/CDK2 and/or mouse WT/S-A Ascl1, as indicated; cells derived from the
injected cell are shown in the side to the right in A. (A) Embryos were subject to in situ hybridisation for AVNAmarkers at stage 18-19, as labelled. (B) Embryos were
scored for marker expression comparing the injected and uninjected side (see supplementary material Fig. S3 for scoring scheme). For scoring data, n=20-32.
Kruskal–Wallis non-parametric ANOVA was performed comparing WT ASCL1 with S-A ASCL1 without and with cyclin A/CDK2 (*P<0.05 and ***P<0.000005).
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TH-expressing cells on the ventral side of the embryo. These results
are consistent with elevated levels of CDKs inhibiting the formation
of NA neurons by directly phosphorylating Ascl1 on SP sites and
preventing its ability to drive differentiation (Ali et al., 2014).
N-Myc inhibits AVNA cell differentiation induced byWTAscl1
but not S-A Ascl1
Although aberrant high CDK activity is clearly associated with NB
(Molenaar et al., 2009, 2008), one of the strongest markers of poor
prognosis for individuals with NB isMYCN amplification (Brodeur,
2003). N-Myc expression driven by the TH promoter causes NB in
mice (Weiss et al., 1997), suggesting that N-Myc is a critical effector
of NB pathogenesis. Furthermore, even in non-MYCN-amplified
tumours, a MYCN-amplified transcriptional signature is observed
(Valentijn et al., 2012), and levels of c-Myc can also be elevated
(Mestdagh et al., 2010), together suggesting that Myc signalling is
an underlying driver of NB tumorigenesis. A role for c-Myc
is established in early neural crest development in Xenopus, where it
is an essential regulator of neural crest precursor cells (Bellmeyer
et al., 2003). Moreover, N-Myc has been demonstrated to promote
proliferation and inhibit differentiation in the CNS (Knoepfler et al.,
2002), and seems to play a similar role in NB (Thiele and Israel,
1988; Thiele et al., 1985).
With this in mind, we investigated whether overexpression of
MYCN affected AVNA differentiation. N-Myc overexpression alone
had little effect on expression of endogenous Hand2, Phox2a or TH
(Fig. 7), indicating that increased expression of N-Myc cannot
perturb the normal differentiation of AVNA cells. Next, in order to
mimic the situation found in some NB cells, in which both ASCL1
and N-Myc protein are highly expressed, we co-injected N-Myc
with levels of WT Ascl1 mRNA that would induce ectopic AVNA
cells. Despite having little effect on the formation of endogenous
AVNA cells, N-Myc overexpression perturbed Ascl1-induced
ectopic AVNA differentiation, significantly reducing ectopic
Hand2 and TH expression (Fig. 7A), reducing overexpression of
these markers from at least 75% of embryos to under 25% (Fig. 7B).
Phox2a staining was relatively unchanged in the majority of the
embryos analysed. Thus, in the presence of elevated levels of Ascl1,
N-Myc suppresses AVNA cell differentiation as shown by a
reduction in Hand2 and TH staining. To determine how the SP
phospho-status of Ascl1 affected the ability of N-Myc to inhibit
Ascl1-induced ectopic AVNA differentiation, S-A Ascl1 mRNA
was co-injected with N-Myc mRNA. In contrast to WT
Ascl1, S-A Ascl1 can still induce AVNA cells in the presence of
elevated N-Myc. Hence, high levels of N-Myc can inhibit
differentiation of AVNA cells driven by elevated WT Ascl1 but
not by elevated S-A Ascl1 (Fig. 7A,B). This indicates that the
suppression of differentiation by N-Myc acts at least partially via the
regulated phosphorylation of Ascl1.
DISCUSSION
NB seems to be an undifferentiated tumour of the sympathetic
nervous system based upon its histological phenotype and its ability
to undergo further neuronal differentiation and maturation with
retinoic acid treatment (Thiele et al., 1985). However, although NB
cells do maintain proliferative potential, they cannot be simply
viewed as very early sympathetic precursor cells because they also
express many of the markers that are associated with differentiated
NA neurons, including Phox2a, Hand2 and TH. Indeed, NA
neurons of the sympathetic nervous system are unique during
normal development in their ability to express markers of
differentiated NA neurons while simultaneously retaining their
proliferative potential (Ernsberger et al., 1989). Given this, NB
might derive from cells that have begun to express markers of the
sympathetic nervous system, but have failed to progress past this
point to full maturity and more importantly have failed to exit the
cell cycle. If this is the case, studying the developmental stage from
which NB arises during development might yield vital insight into
both NB pathogenesis and potential modes of treatment. However,
the inaccessibility and migratory nature of these cells has made their
characterisation particularly problematic in mammalian systems. In
this study we have shown that the AVNA cells in Xenopus, which
were first identified by Parlier and colleagues (2008), represent a
useful model to investigate mechanisms contributing to NB
formation and maintenance. Moreover, elucidation of crucial
mechanisms regulating these cells provides a platform to explore
new therapeutic approaches for this devastating disease.
We find that Xenopus AVNA cells share characteristics of NB
cells. Firstly, these cells are derived from migrating neural crest and
express key markers of sympathetic nervous system development.
When migration of these neural crest precursors to the anteroventral
region is prevented by dnSlug, the neural crest cells that remain at the
neural folds do not express the markers of NA neurons. This failure
to differentiate is potentially the result of improper extracellular
signalling in the anteroventral region; for example, BMP2 signals,
which are required for normal NA development in mammals
(Howard, 2005) and for AVNA cells inXenopus (Parlier et al., 2008)
are not received. This is particularly interesting because BMP2
signalling has also been shown to play a role in differentiation of NB
cells (Nakamura et al., 2003). Secondly, these AVNA cells express
known NA markers also found in NB cells, such as Hand2, Phox2a
and TH. AVNA and NB cells also express Ascl1. Ascl1 is only
expressed transiently in AVNA differentiation (Parlier et al., 2008)
(Fig. 2), whereas NB tumours and almost all NB cell lines have high
levels of ASCL1 expression, indicating that NB cells are stalled at
this transient stage of NA neuron development. This observation
allows us to pinpoint much more closely the developmental window
from which NB cells are likely to arise. Interestingly, ASCL1 levels
are found to rapidly decrease when NB cells continue differentiation
upon treatment with retinoic acid (Söderholm et al., 1999),
supporting the hypothesis that NB cells are trapped in a transient
phase of development. Thirdly, Xenopus primary neurons require
cell cycle exit to undergo differentiation (Vernon et al., 2003),
whereas differentiation of AVNA cells show a reduced requirement
for this (Fig. 3). Nevertheless, increasing CDK levels does suppress
differentiation of both endogenous AVNA cells and ectopic neurons
generated after Ascl1 overexpression (Fig. 6).
Ascl1 is a powerful proneural transcription factor, driving both
extensive neurogenesis in ectoderm and in neural precursors of the
CNS (Ali et al., 2014; Castro et al., 2011), as well as playing a key role
in a transcription factor cocktail that can reprogramme mammalian
fibroblasts directly into neurons (Pang et al., 2011; Vierbuchen et al.,
2010).Whywould such a potent inducerof neuronal differentiationbe
elevated in NBwhere these cells fail to adopt their developmental fate
and instead proliferate with little control? Recent evidence has shown
that, at endogenous levels found at specific stages of development,
Ascl1 supports and indeed is essential for proliferation of neural stem
cells in the CNS (Castro et al., 2011). However, higher levels of Ascl1
result in cell cycle exit anddifferentiation (Ali et al., 2014;Castro et al.,
2011).We see that the ability ofAscl1 to drive neuronal differentiation
in development is not only controlled by the level of the protein but
also by its phospho-status (Ali et al., 2014) (Figs 5-7), and that Ascl1
can be phosphorylated by CDKs in a cell-cycle-dependent manner
(Ali et al., 2014).
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Fig. 7. N-Myc inhibits AVNA cell differentiation induced by WTASCL1 but not S-A ASCL1. Xenopus embryos were injected in one cell at the two-cell stage
with β-galactosidase (light blue; A) as a tracer along with mRNA encoding N-Myc with or without mouseWT/S-A Ascl1, as indicated. (A) Embryos were subject to
in situ hybridisation for AVNA markers as indicated at stage 18-19. (B) Embryos were scored for marker expression comparing the injected and uninjected side
(see supplementary material Fig. S3 for scoring scheme). For scoring data, n=24-32. Kruskal–Wallis non-parametric ANOVA was performed comparing WT
ASCL1 and S-A ASCL1 with and without N-Myc (*P<0.05, **P<0.0005 and ***P<0.000005).
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Much of Ascl1’s ability to induce expression of NA markers is
probably due to an indirect transcriptional cascade. None of the NA
markers (Phox2a, Hand2 or TH) has been shown to be a direct
downstream target of Ascl1 (Castro et al., 2011), but they are
upregulated sequentially during development (Howard, 2005;
Rohrer, 2011). For instance, Hand2 is particularly important for
the generation of NA neurons because it regulates expression of TH
(Lei and Howard, 2011). Although the direct connections between
Ascl1 and neuronal differentiation in the peripheral nervous system
is less clear than in the CNS, Ascl1 overexpression does result in
expression of NA markers in Xenopus embryos (Figs 6 and 7),
suggesting some analogy between the function of Ascl1 in the
peripheral and central nervous systems.
Ascl1 is found in multiply phosphorylated forms in almost all NB
cell lines (Fig. 5). Hence, we sought to use the Xenopus AVNA
system to investigate the effect of elevated CDK levels on AVNA
cell differentiation and whether effects seen are mediated by
phosphorylation of Ascl1 in the developing embryo. We see that
elevated CDK suppresses differentiation of AVNA cells and this is
dependent on Ascl1-dependent phosphorylation (Fig. 6). This is
consistent with a model whereby high levels of CDK, characteristic
of NB cells (Molenaar et al., 2008), not only promote cell cycling
but also inhibit NA cell differentiation directly via phosphorylation
of endogenous Ascl1. Sympathetic progenitor cells are known to
maintain their proliferative potential while expressing NA markers
such as Ascl1, Phox2a, Hand2 and TH (Ernsberger et al., 1989;
Rohrer, 2011), although we observed decreased expression of these
markers on CDK hyperactivation (Fig. 6). Hence, lower levels of
CDK activity that will be required to support progenitor
maintenance seem to be permissive for NA gene expression.
However, higher CDK levels produced in our overexpression
studies did suppress expression of these NA markers, and a similar
situation is potentially found in NB cell tumours. Little is known
about the effects of slowing (as opposed to arresting) the cell cycle
on differentiation in the PNS, but, during development of CNS
neurons, an initial slowing of the cell cycle rather than a complete
halt ultimately promotes neuronal differentiation (Lange et al.,
2009). This raises the possibility of using low levels of CDKIs to
promote differentiation during NB treatment (Molenaar et al., 2008;
Rader et al., 2013).
N-Myc has little effect on AVNA cell differentiation during
normal development, when Ascl1 is only transiently expressed.
However, ectopic N-Myc inhibits the ability of cells expressing
elevated Ascl1 from undergoing AVNA differentiation and is
perhaps analogous to the situation in NB, where both N-Myc and
Ascl1 levels remain high. N-Myc-mediated inhibition of
differentiation in AVNA cells also occurs via a mechanism
involving Ascl1 phosphorylation on SP sites. This is consistent
with N-Myc being found in the most aggressive NBs and its inverse
association with differentiation in vitro (Thiele and Israel, 1988;
Thiele et al., 1985).
Taken together, our data not only identify a developmentally
relevant stage at which stalled differentiation might result in NB cell
formation but also suggest a possible mechanism for suppression of
NA differentiation within this population. NA cells with perhaps
abnormally high or prolonged CDK activity, although passing
through the developmental window of high ASCL1 expression, will
result in the maintenance of ASCL1 protein in its highly
phosphorylated form. This hyper-phosphorylated ASCL1 might
play a direct role in promoting ‘stem-ness’ in the NA precursor
population, and prevent these cells from undergoing further
differentiation [a process that requires un(der)phosphorylated
ASCL1]. If cells fail to pass through the developmental window
of transient high ASCL1 expression, followed by differentiation
and subsequent ASCL1 downregulation, these elevated levels of
phosphorylated ASCL1 would cause NB precursors to remain in
cycle, and cells would be able to accumulate further epigenetic or
genetic ‘hits’ such as MYCN amplification and chromosomal
rearrangements, driving tumour progression. Moreover, N-Myc
amplification will further drive proliferation, potentially by feeding
the maintenance of phospho-ASCL1.
The advancement of Xenopus as a model to gain a greater
understanding of the cell cycle and transcriptional events of NA cell
formation will surely provide a very versatile system, not only to
study normal NA neuron differentiation, but it will also act as a
uniquely tractable model to explore mechanisms that can perturb or
promote this differentiation in disease and its therapy.
MATERIALS AND METHODS
Xenopus laevis extracts and embryos
Acquisition of Xenopus laevis eggs and embryos, preparation and injection
of synthetic mRNA and DNA MOs, staging of embryos, and in situ
hybridisation were undertaken as described previously (Vernon et al., 2003;
Vosper et al., 2007, 2009). Scoring standards for each marker are shown in
supplementary material Fig. S3. Xenopus experiments were carried out
according to institutional standards of the University of Cambridge and
under licence from the UK Government Home Office.
Cell culture and western blotting
NB cells were cultured in RPMI-1640 (Gibco) with 10% fetal bovine serum
(Atlanta Biologicals), 1% Glutamax (Gibco) and 100 units/ml penicillin/
100 µg/ml streptomycin (Sigma). Cells were lysed with RIPA buffer
[150 mM NaCl, 1.0% IGEPAL® CA-630 (Sigma), 0.5% sodium
deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0] and treated with
Lambda Protein Phosphatase (New England BioLabs) to determine ASCL1
phospho-shift. Following electrophoresis, membranes were incubated with
an anti-ASCL1 [a kind gift from David Anderson and Francois Guillemot
(Castro et al., 2011)] and anti-Gapdh (Sigma), and imaged using
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Quantitative real-time PCR (qPCR)
cDNAwas generated from NB cells and 50 ng used per qPCR reaction in a
Light-Cycler 480 PCR system with SYBR Green mix (Roche). HPRT1 and
GAPDH were used as house-keeping genes. Thermal cycling conditions:
95°C for 5 min, then 45 cycles of 95°C for 10 s, 60°C for 10 s and 72°C for
10 s. Primer sequences are in supplementary material Table S1.
Generation of lentivirally transduced cell lines
Viral constructs were generated by site-directed mutagenesis using the
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies)
and cloned into a 3rd Gen Lenti-X vector (Clontech) using In-Fusion® HD
Cloning Kit User Manual (Clontech). Viral constructs were made by
transfecting HEK293 cells with 250 mM calcium phosphate and the vector
of interest, and packaging mix: PMD2G, PMLg, REV/PRSV in a ratio of
6:3:4:2, respectively. Virus was titered using the Lenti-X™ qRT-PCR
Titration Kit (Clontech). SY5Y NB cells were transduced with a Tet-On
transactivator (LVX-Tet3G) at a multiplicity of infection (MOI) of 10. After
48 h, cells were selected with 500 µg/ml G418 for 72 h based on a
previously determined optimal antibiotic kill curve. These cells were then
transduced with LVX-TRE3G- encoding either human WT ASCL1 or S-A
ASCL1 at an MOI of 10 and then selected after 48 h with 1 µg/ml
puromycin for 72 h based on previously determined kill curves. Cells were
induced with 1 µg/ml of doxycycline (Sigma).
Microarray analysis of NB and normal tissues
Analysis was performed using R2: microarray analysis and visualisation
platform (http://r2.amc.nl). Analysis was performed using the Megasampler
algorithm to analyse expression across datasets. NB tumour data was from
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NB88 [R2 annotation: Tumor Neuroblastoma–Versteeg–88–MAS5.0–
u133p2; accession no. GSE16476] and normal tissue data was from
Roth504 [Normal Various–Roth–504–MAS5.0–u133p2; accession no.
GSE7307]. Expression levels were normalised using the MASS5.0
algorithm (Affymetrix, Inc.).
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Söderholm, H., Örtoft, E., Johansson, I., Ljungberg, J., Larsson, C., Axelson, H.
and Pahlman, S. (1999). Human achaete-scute homologue 1 (HASH-1) is
downregulated in differentiating neuroblastoma cells. Biochem. Biophys. Res.
Commun. 256, 557-563.
Sonnenberg-Riethmacher, E., Miehe, M., Stolt, C. C., Goerich, D. E.,Wegner, M.
and Riethmacher, D. (2001). Development and degeneration of dorsal root
ganglia in the absence of the HMG-domain transcription factor Sox10.Mech. Dev.
109, 253-265.
Southard-Smith, E. M., Kos, L. and Pavan, W. J. (1998). Sox10 mutation disrupts
neural crest development inDomHirschsprungmousemodel.Nat.Genet.18, 60-64.
Talikka, M., Stefani, G., Brivanlou, A. H. and Zimmerman, K. (2004).
Characterization of Xenopus Phox2a and Phox2b defines expression domains
within the embryonic nervous system and early heart field.Gene Expr. Patterns 4,
601-607.
Thiele, C. J. and Israel, M. A. (1988). Regulation of N-myc expression is a critical
event controlling the ability of human neuroblasts to differentiate. Exp. Cell Biol.
56, 321-333.
Thiele, C. J., Reynolds, C. P. and Israel, M. A. (1985). Decreased expression of N-
myc precedes retinoic acid-induced morphological differentiation of human
neuroblastoma. Nature 313, 404-406.
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